Will Gil Blum’s Upgrade Shift Amicus Therapeutics’ (FOLD) Growth Narrative and Risk Profile?

• In early October 2025, Needham analyst Gil Blum upgraded Amicus Therapeutics, highlighting an improved outlook for the company’s future prospects.
• This development could impact investor confidence, as analyst recommendations are often closely monitored within the biotechnology sector.
• We'll explore how this analyst upgrade and the improved outlook may influence Amicus Therapeutics' growth narrative and risk profile.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Amicus Therapeutics Investment Narrative Recap

To be a shareholder in Amicus Therapeutics, you have to believe in the company’s ability to capture more of the large, underserved market for rare diseases like Fabry and Pompe, despite intense competition and a heavy reliance on a few products. The recent upgrade by Needham’s Gil Blum may boost short-term investor sentiment, but it does not fundamentally change the key catalyst: sustained revenue growth from new patient uptake and geographic expansion. The core risk of concentrated revenue and competition remains unchanged.

Of the latest company developments, the September 2025 presentation of new four-year data showing improved muscle strength for Pompe disease patients treated with Pombiliti and Opfolda is closely tied to this upgrade. These results support the narrative of ongoing adoption and could reinforce optimism sparked by the analyst’s improved outlook, making product performance and competitive positioning all the more vital for near-term momentum.

Yet, despite the positive tone, investors should not overlook the ongoing risk posed by substantial net losses and potential funding needs if cash flows do not…

Read the full narrative on Amicus Therapeutics (it's free!)

Amicus Therapeutics' outlook anticipates $995.5 million in revenue and $234.9 million in earnings by 2028. This reflects a forecasted annual revenue growth rate of 20.3% and an earnings increase of $273 million from current earnings of -$38.1 million.

Uncover how Amicus Therapeutics' forecasts yield a $15.36 fair value, a 87% upside to its current price.

Exploring Other Perspectives

Four individual valuations from the Simply Wall St Community place Amicus Therapeutics’ fair value between US$13.96 and US$58.56 a share. While many see room for upside, ongoing net losses and future funding requirements remain front of mind for shareholders considering the company’s long term financial health.

Explore 4 other fair value estimates on Amicus Therapeutics - why the stock might be worth over 7x more than the current price!

Build Your Own Amicus Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Amicus Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Amicus Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amicus Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com